Finally! Shire And Baxalta Sign $32bn Deal To Form Largest Rare Disease Company

Shire plc and Baxalta Incorporated have confirmed they are to merge. The combined company, which will be 34% owned by Baxalta shareholders, will be "the partner of choice in rare diseases," claimed Shire CEO Flemming Ornskov.

Shire plc and Baxalta Incorporated have confirmed they are to merge. The combined company, which will be 34% owned by Baxalta shareholders, will be "the partner of choice in rare diseases," claimed Shire CEO Flemming Ornskov.

Ornskov said the deal would see Shire achieve $20bn in annual revenues by 2020, compared with $10bn prior to the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category